Lonza upgrades organic growth model and mid-term financial ambitions
The CDMO updates targets to low-teens sales growth and high-thirties EBITDA margin following pure-play transformation completion. Q3 2026 results aligned with expectations.
See the latest news and media coverage for Lonza. We track all announcements, press releases, and industry mentions in real time, all in one place.
Dedicated CDMO serving the healthcare industry
lonza.comLast updated
In short: Lonza delivered strong H1 2026 results, raised margin targets, and advanced major capacity and technology investments.
The CDMO updates targets to low-teens sales growth and high-thirties EBITDA margin following pure-play transformation completion. Q3 2026 results aligned with expectations.
The company upgraded its full-year margin outlook and saw double-digit growth across all platforms.
The expansion adds two biologics programs for commercial production, with potential multi-billion CHF value.
Confirms full-year outlook with 11-12% sales growth and EBITDA margin above 32%. Completes transformation to pure-play CDMO via CHI divestment.
Lonza Group shares climbed 2.5% following the company’s announcement of upgraded mid-term financial targets and confirmation ...
The pharmaceutical contract manufacturer plans organic growth of 10-13% annually.
Lonza's first-half 2026 sales reached CHF 3.4 billion, representing 16 percent growth at constant exchange rates from H1 2025. Core EBITDA rose 27.4 percent to...
Lonza is adding large-scale commercial capacity in the USA, with a new plant at its Bend, Oregon site that the company says will make it...
Track Lonza and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lonza and other trending companies.